Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

OPTIMARK

GADOVERSETAMIDE

Standard Dose
16.545GM/50ML (330.9MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview OPTIMARK is listed in Drugs@FDA under application 020975 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient GADOVERSETAMIDE Form and strength INJECTABLE;INJECTION - 16.545GM/50ML (330.9MG/ML) Sponsor LIEBEL-FLARSHEIM Submission history Latest submission status date: 2018-11-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview OPTIMARK is listed in Drugs@FDA under application 020975 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient GADOVERSETAMIDE Form and strength INJECTABLE;INJECTION - 16.545GM/50ML (330.9MG/ML) Sponsor LIEBEL-FLARSHEIM Submission history Latest submission status date: 2018-11-02 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.